Insulin nomenclature is clearly confusing. Among other reasons:
The same product may have several different names; the names may be different in the U.S. compared to other countries; the same product may be made by several manufacturers and given differing names.
The product may be from different sources (previously all insulin came from animal pancreases: beef, pork, or mixed beef/pork; but now-a-days, insulins usually are semisynthetic human).
Insulins are classified by duration of action, as being rapid, intermediate, and prolonged.
Several manufacturers may also mix two insulin products into the same vial, producing mixtures of 70% one and 30% another, or 50/50. To make it worse, what the US calls 70/30 would be called 30/70 in Europe! And in the US, 70/30, 75/25, and 50/50 are the usual mixtures, but in Europe there will be others such as 80/20 (oops, 20/80).
Some of the "big players" in the insulin arena are described below. I give the U.S. brand name first, then common na...
have done my research! After reading Health Central's DiabeTeens.com , along with
questions and concerns from my own teen patients with diabetes , it appears that
insulin pump therapy is a hot topic! As of June 14, the featured poll (how do you feel about the pump) results are: love it--51percent;
hate it--9 percent; never tried it--40 percent. If 40 percent of our readers
have no experience with the pump, then there are a lot of kids out there that
need this information.
key to making any important decision, especially regarding your insulin
management, is to learn as much as possible before making a choice. Knowledge
is power! So, let's talk about your choices. Keep in mind (and this is very important) that there is no one RIGHT way to do things-including diabetes
management . My own practice is to offer choices, provide medically correct
information, discuss positives and negatives of each form of therapy, and support
the decision of my teens. (Along with offering my very...
If you forgot to test, you’re in good company. It seems that the scientific researchers whom you rely on for your professional guidance on diabetes made the same mistake. When they tested the short-acting insulins, they forgot that the great majority of us with type 2 diabetes carry around too much weight. This awful report just came out in a late-breaking abstract presented at the American Diabetes Association’s scientific sessions in Chicago . Dr. Jean L. Ardilouze, a professor of medicine at University of Sherbrooke in Quebec, Canada, and three colleagues presented “In Obese Subjects with Type 2 Diabetes, Are Short Acting Insulin Analogues That Short?” Their conclusion was this: In healthy normal weight subjects, our results reproduced data accepted and used in daily practice for insulin prescriptions. However, in a population of obese subjects with type 2 diabetes, we show for the first time that plasma levels of short-acting insulins are blunted, at low dosage, and severely delay...
You should knowAnswers to your question are meant to provide general health information but should not replace medical advice you receive from a doctor. No answers should be viewed as a diagnosis or recommended treatment for a condition. Content posted by community members does not necessarily reflect the views of Remedy Health Media, which also reserves the right to remove material deemed inappropriate.